Geode Capital Management
KALV

Geode Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Geode Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.1M Buy
996,235
+52,158
+6% +$841K ﹤0.01% 1989
2025
Q4 		$15.3M Buy
944,077
+15,406
+2% +$204K ﹤0.01% 2159
2025
Q3 		$11.3M Sell
928,671
-12,541
-1% -$173K ﹤0.01% 2350
2025
Q2 		$10.6M Buy
941,212
+25,971
+3% +$318K ﹤0.01% 2328
2025
Q1 		$10.6M Buy
915,241
+92,889
+11% +$948K ﹤0.01% 2262
2024
Q4 		$6.97M Sell
822,352
-8,632
-1% -$89.4K ﹤0.01% 2568
2024
Q3 		$9.62M Buy
830,984
+24,713
+3% +$311K ﹤0.01% 2402
2024
Q2 		$9.5M Buy
806,271
+154,383
+24% +$1.8M ﹤0.01% 2350
2024
Q1 		$7.73M Buy
651,888
+21,840
+3% +$291K ﹤0.01% 2477
2023
Q4 		$7.72M Buy
630,048
+108,157
+21% +$984K ﹤0.01% 2474
2023
Q3 		$5.03M Buy
521,891
+41,466
+9% +$424K ﹤0.01% 2637
2023
Q2 		$4.32M Buy
480,425
+12,941
+3% +$119K ﹤0.01% 2768
2023
Q1 		$3.67M Buy
467,484
+69,409
+17% +$518K ﹤0.01% 2768
2022
Q4 		$2.69M Sell
398,075
-16,784
-4% -$89.9K ﹤0.01% 2933
2022
Q3 		$6.02M Buy
414,859
+17,844
+4% +$249K ﹤0.01% 2569
2022
Q2 		$3.91M Sell
397,015
-12,011
-3% -$133K ﹤0.01% 2831
2022
Q1 		$6.03M Buy
409,026
+31,056
+8% +$446K ﹤0.01% 2689
2021
Q4 		$5M Buy
377,970
+9,830
+3% +$156K ﹤0.01% 2903
2021
Q3 		$6.42M Buy
368,140
+30,863
+9% +$626K ﹤0.01% 2767
2021
Q2 		$8.08M Buy
337,277
+10,010
+3% +$262K ﹤0.01% 2613
2021
Q1 		$8.41M Buy
327,267
+101,848
+45% +$2.68M ﹤0.01% 2472
2020
Q4 		$4.28M Buy
225,419
+17,542
+8% +$301K ﹤0.01% 2683
2020
Q3 		$2.62M Buy
207,877
+9,592
+5% +$120K ﹤0.01% 2735
2020
Q2 		$2.4M Buy
198,285
+6,616
+3% +$70.4K ﹤0.01% 2747
2020
Q1 		$1.47M Buy
191,669
+27,763
+17% +$375K ﹤0.01% 2836
2019
Q4 		$2.92M Buy
163,906
+12,125
+8% +$158K ﹤0.01% 2774
2019
Q3 		$1.76M Buy
151,781
+9,912
+7% +$160K ﹤0.01% 3008
2019
Q2 		$3.14M Buy
141,869
+58,774
+71% +$1.38M ﹤0.01% 2664
2019
Q1 		$2.38M Sell
83,095
-786
-0.9% -$17K ﹤0.01% 2750
2018
Q4 		$1.66M Buy
83,881
+19,636
+31% +$395K ﹤0.01% 2865
2018
Q3 		$1.42M Buy
64,245
+43,483
+209% +$588K ﹤0.01% 3069
2018
Q2 		$168K Hold
20,762
– – ﹤0.01% 3763
2018
Q1 		$196K Hold
20,762
– – ﹤0.01% 3697
2017
Q4 		$202K Buy
+20,762
New +$216K ﹤0.01% 3669
2016
Q4 		– Sell
-4,794
Closed -$30K – 4047
2016
Q3 		$30K Buy
4,794
+7
+0.1% +$53 ﹤0.01% 3967
2016
Q2 		$44K Sell
4,787
-724
-13% -$8.38K ﹤0.01% 3948
2016
Q1 		$49 Sell
5,511
-7
-0.1% -$125 ﹤0.01% 3969
2015
Q4 		$279K Buy
5,518
+116
+2% +$6.07K ﹤0.01% 3544
2015
Q3 		$269K Buy
+5,402
New +$460K ﹤0.01% 3534

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management's KALV Position: Q1 2026 in Review

Geode Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 5.5% in Q1 2026, buying an estimated $841K and bringing the position to 996,235 shares worth $20.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Geode Capital Management first reported a position in KALV in Q3 2015 and has held it in 39 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Geode Capital Management held 996,235 shares of KalVista Pharmaceuticals worth $20.1M as of Q1 2026.
  • Geode Capital Management bought 52,158 KalVista Pharmaceuticals shares in Q1 2026, an estimated $841K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1989 holding.
  • Geode Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2015 and has held it in 39 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.